Aptose Price To Sales Ratio vs Payables Turnover Analysis

APTO Stock

USD 0.19 0.01 5.56%

Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Price To Sales Ratio and its Payables Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Price To Sales Ratio account and Payables Turnover. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aptose Biosciences' Price To Sales Ratio and Payables Turnover is -0.09. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Payables Turnover in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Price To Sales Ratio and Payables Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Aptose Biosciences are associated (or correlated) with its Payables Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Payables Turnover has no effect on the direction of Price To Sales Ratio i.e., Aptose Biosciences' Price To Sales Ratio and Payables Turnover go up and down completely randomly.

Correlation Coefficient

-0.09

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Aptose Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aptose Biosciences sales, a figure that is much harder to manipulate than other Aptose Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 15th of December 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 5.8 M.

	2021	2022	2023	2024 (projected)
Net Interest Income	94K	788K	1.4M	1.5M
Interest Income	94K	788K	1.4M	1.5M

Net Interest Income Interest Income

Aptose Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Common Stock Total Equity	Short Term Debt	Common Stock
Total Assets		0.23	0.25	0.99	0.74	-0.97	-0.39	0.18	0.96	0.55	0.64	1.0	0.51	0.56	0.11	0.43	0.37	0.28	0.08	1.0	-0.02	-0.19	0.93	0.47	0.3	0.72
Other Current Liab	0.23		0.98	0.1	0.56	-0.17	-0.92	0.91	0.2	0.73	-0.08	0.21	0.93	0.16	0.1	0.87	0.95	0.97	0.83	0.23	0.89	-0.27	0.46	0.88	-0.01	0.67
Total Current Liabilities	0.25	0.98		0.12	0.63	-0.21	-0.93	0.97	0.25	0.78	-0.03	0.22	0.94	0.09	0.23	0.87	0.96	1.0	0.81	0.24	0.91	-0.27	0.47	0.88	0.0	0.69
Total Stockholder Equity	0.99	0.1	0.12		0.67	-0.96	-0.27	0.05	0.96	0.46	0.66	0.99	0.4	0.56	0.08	0.32	0.25	0.15	-0.02	0.99	-0.14	-0.16	0.89	0.37	0.31	0.64
Property Plant And Equipment Net	0.74	0.56	0.63	0.67		-0.71	-0.63	0.64	0.72	0.85	0.49	0.73	0.73	0.33	0.32	0.54	0.64	0.65	0.43	0.74	0.46	-0.09	0.75	0.7	0.1	0.81
Net Debt	-0.97	-0.17	-0.21	-0.96	-0.71		0.34	-0.17	-1.0	-0.54	-0.73	-0.97	-0.46	-0.34	-0.16	-0.37	-0.3	-0.24	-0.11	-0.97	0.07	0.2	-0.91	-0.45	-0.39	-0.66
Retained Earnings	-0.39	-0.92	-0.93	-0.27	-0.63	0.34		-0.87	-0.37	-0.72	-0.11	-0.36	-0.95	-0.2	-0.25	-0.85	-0.93	-0.93	-0.67	-0.38	-0.81	0.54	-0.57	-0.94	-0.18	-0.84
Accounts Payable	0.18	0.91	0.97	0.05	0.64	-0.17	-0.87		0.2	0.78	-0.01	0.15	0.88	-0.02	0.33	0.8	0.91	0.97	0.75	0.17	0.93	-0.23	0.38	0.81	-0.07	0.64
Cash	0.96	0.2	0.25	0.96	0.72	-1.0	-0.37	0.2		0.57	0.73	0.96	0.49	0.33	0.17	0.4	0.33	0.28	0.15	0.96	-0.04	-0.21	0.92	0.47	0.4	0.66
Non Current Assets Total	0.55	0.73	0.78	0.46	0.85	-0.54	-0.72	0.78	0.57		0.34	0.53	0.8	0.16	0.24	0.64	0.75	0.8	0.66	0.55	0.63	-0.14	0.66	0.79	0.14	0.65
Other Assets	0.64	-0.08	-0.03	0.66	0.49	-0.73	-0.11	-0.01	0.73	0.34		0.65	0.17	0.03	0.49	-0.07	0.02	-0.01	0.08	0.64	-0.31	-0.15	0.59	0.25	0.4	0.37
Cash And Short Term Investments	1.0	0.21	0.22	0.99	0.73	-0.97	-0.36	0.15	0.96	0.53	0.65		0.49	0.56	0.1	0.4	0.34	0.25	0.06	1.0	-0.05	-0.18	0.92	0.45	0.3	0.7
Common Stock Shares Outstanding	0.51	0.93	0.94	0.4	0.73	-0.46	-0.95	0.88	0.49	0.8	0.17	0.49		0.27	0.16	0.92	0.97	0.94	0.7	0.51	0.79	-0.31	0.67	0.93	0.09	0.84
Short Term Investments	0.56	0.16	0.09	0.56	0.33	-0.34	-0.2	-0.02	0.33	0.16	0.03	0.56	0.27		-0.12	0.25	0.25	0.1	-0.17	0.56	0.01	-0.05	0.49	0.2	-0.16	0.43
Non Current Liabilities Total	0.11	0.1	0.23	0.08	0.32	-0.16	-0.25	0.33	0.17	0.24	0.49	0.1	0.16	-0.12		-0.04	0.16	0.24	0.12	0.1	0.13	-0.3	0.14	0.24	0.18	0.24
Other Current Assets	0.43	0.87	0.87	0.32	0.54	-0.37	-0.85	0.8	0.4	0.64	-0.07	0.4	0.92	0.25	-0.04		0.91	0.86	0.58	0.42	0.78	-0.24	0.58	0.82	0.1	0.73
Other Stockholder Equity	0.37	0.95	0.96	0.25	0.64	-0.3	-0.93	0.91	0.33	0.75	0.02	0.34	0.97	0.25	0.16	0.91		0.96	0.69	0.36	0.85	-0.22	0.54	0.88	0.04	0.77
Total Liab	0.28	0.97	1.0	0.15	0.65	-0.24	-0.93	0.97	0.28	0.8	-0.01	0.25	0.94	0.1	0.24	0.86	0.96		0.81	0.27	0.91	-0.27	0.49	0.88	0.0	0.7
Property Plant And Equipment Gross	0.08	0.83	0.81	-0.02	0.43	-0.11	-0.67	0.75	0.15	0.66	0.08	0.06	0.7	-0.17	0.12	0.58	0.69	0.81		0.08	0.65	-0.11	0.38	0.67	-0.03	0.37
Total Current Assets	1.0	0.23	0.24	0.99	0.74	-0.97	-0.38	0.17	0.96	0.55	0.64	1.0	0.51	0.56	0.1	0.42	0.36	0.27	0.08		-0.02	-0.19	0.93	0.47	0.3	0.71
Non Currrent Assets Other	-0.02	0.89	0.91	-0.14	0.46	0.07	-0.81	0.93	-0.04	0.63	-0.31	-0.05	0.79	0.01	0.13	0.78	0.85	0.91	0.65	-0.02		-0.21	0.16	0.72	-0.2	0.51
Intangible Assets	-0.19	-0.27	-0.27	-0.16	-0.09	0.2	0.54	-0.23	-0.21	-0.14	-0.15	-0.18	-0.31	-0.05	-0.3	-0.24	-0.22	-0.27	-0.11	-0.19	-0.21		-0.29	-0.47	-0.44	-0.45
Net Tangible Assets	0.93	0.46	0.47	0.89	0.75	-0.91	-0.57	0.38	0.92	0.66	0.59	0.92	0.67	0.49	0.14	0.58	0.54	0.49	0.38	0.93	0.16	-0.29		0.66	0.31	0.77
Common Stock Total Equity	0.47	0.88	0.88	0.37	0.7	-0.45	-0.94	0.81	0.47	0.79	0.25	0.45	0.93	0.2	0.24	0.82	0.88	0.88	0.67	0.47	0.72	-0.47	0.66		0.32	0.82
Short Term Debt	0.3	-0.01	0.0	0.31	0.1	-0.39	-0.18	-0.07	0.4	0.14	0.4	0.3	0.09	-0.16	0.18	0.1	0.04	0.0	-0.03	0.3	-0.2	-0.44	0.31	0.32		0.27
Common Stock	0.72	0.67	0.69	0.64	0.81	-0.66	-0.84	0.64	0.66	0.65	0.37	0.7	0.84	0.43	0.24	0.73	0.77	0.7	0.37	0.71	0.51	-0.45	0.77	0.82	0.27

Click cells to compare fundamentals

Aptose Biosciences Account Relationship Matchups

Aptose Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Other Current Liab	3.1M	3.6M	6.0M	5.7M	8.8M	9.3M
Total Current Liabilities	5.5M	6.8M	8.2M	12.3M	15.3M	16.0M
Total Stockholder Equity	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Property Plant And Equipment Net	1.7M	1.2M	788K	1.5M	1.1M	574.5K
Net Debt	(78.3M)	(116.3M)	(38.5M)	(35.7M)	(8.2M)	(8.6M)
Retained Earnings	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(515.5M)	(489.8M)
Accounts Payable	2.0M	2.2M	1.7M	6.3M	6.0M	6.3M
Cash	79.8M	117.4M	39.1M	37.0M	9.3M	15.8M
Non Current Assets Total	1.7M	1.2M	788K	1.5M	1.1M	1.7M
Cash And Short Term Investments	97.6M	122.4M	79.1M	47.0M	9.3M	8.8M
Common Stock Shares Outstanding	3.3M	5.5M	5.9M	6.2M	6.8M	7.1M
Short Term Investments	798K	440K	17.8M	5M	40.0M	10.0M
Liabilities And Stockholders Equity	100.5M	126.3M	82.5M	51.0M	13.0M	12.3M
Non Current Liabilities Total	1.0M	535K	115K	1.0M	621K	590.0K
Other Current Assets	141K	2.7M	2.6M	2.6M	2.6M	2.8M
Other Stockholder Equity	34.6M	50.9M	63.7M	68.9M	72.1M	75.8M
Total Liab	6.6M	7.3M	8.3M	13.3M	15.9M	16.7M
Property Plant And Equipment Gross	1.7M	1.2M	323K	211K	3.9M	4.1M
Total Current Assets	98.8M	125.1M	81.7M	49.5M	11.9M	11.3M
Non Currrent Assets Other	(94.0)	(48.0)	465K	1.3M	1.2M	1.2M
Intangible Assets	1.0	142.0	94.0	48.0	43.2	41.04
Net Tangible Assets	93.8M	118.9M	74.2M	37.7M	43.4M	45.6M
Common Stock Total Equity	365.5M	429.5M	437.4M	437.5M	503.1M	528.3M
Retained Earnings Total Equity	(301.9M)	(357.2M)	(422.5M)	(464.3M)	(417.9M)	(397.0M)
Common Stock	365.5M	429.5M	437.4M	437.5M	444.8M	231.5M
Property Plant Equipment	1.6M	1.1M	788K	211K	189.9K	364.1K
Capital Surpluse	34.6M	50.9M	63.7M	68.9M	79.2M	51.4M
Net Invested Capital	93.9M	118.9M	74.2M	37.7M	(2.9M)	(2.8M)
Net Working Capital	93.2M	118.3M	73.6M	37.2M	(3.4M)	(3.2M)
Capital Stock	365.5M	429.5M	437.4M	437.5M	444.8M	435.6M

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptose Stock

0.88	VALN	Valneva SE ADR	Pair Corr
0.89	ERNA	Eterna Therapeutics	Pair Corr

Moving against Aptose Stock

0.94	DYAI	Dyadic International	Pair Corr
0.82	ESPR	Esperion Therapeutics	Pair Corr
0.7	BMY	Bristol Myers Squibb	Pair Corr
0.53	GILD	Gilead Sciences Sell-off Trend	Pair Corr
0.51	DNA	Ginkgo Bioworks Holdings	Pair Corr

The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.

The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:

How To Invest In Aptose

Details

Is Aptose Stock a good investment?

Details

What is Aptose Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.92)

Return On Assets

(1.36)

Return On Equity

(6.94)

The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptose Price To Sales Ratio vs Payables Turnover Analysis

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Payables Turnover

Aptose Biosciences fundamental ratios Correlations

Aptose Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptose Biosciences fundamental ratios Accounts

Pair Trading with Aptose Biosciences

Moving together with Aptose Stock

Moving against Aptose Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Cash	- 1.0	Net Debt
Total Current Assets	- 0.97	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Net Debt	- 0.96	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.95	Retained Earnings